In the weeks surrounding the 2026 annual meeting of the American Society of Clinical Oncology, my phone buzzed with warnings about GLP-1 drugs and cancer. gave The headlines were everywhere. — from NPR and The Washington Post to substacks and heated exchanges on social media — all revolved around the identical claim: Ozempic can reduce cancer risk.

Behind these headlines is one. A real wave of studyWhich includes hundreds of thousands of patients. I’m one. Physician and medical epidemiologistand my team and I design and interpret the identical sorts of studies that test what widely used drugs actually do.

Excitement around the concept that GLP-1 drugs can prevent cancer is running out of evidence. Not mistaken, vital. Not yet earned.

Cancer is one of the vital difficult things to review, since it is just not one disease but greater than 100. Breast cancer, lung cancer and blood cancer usually are not variations of the identical disease. Each has its own unique biology and its own mixture of genetic, environmental and behavioral risks.

No single drug ever gets a definitive answer on the way it affects cancer. It falls asleep, increasing the chance for some, reducing it for others and leaving most untouched.

Early cancer concerns

Before the present buzz that GLP-1 drugs might reduce cancer risk, concern went in the other way: that they could increase cancer risk.

Researchers were originally concerned about thyroid cancer. Studies in mice have found that Ozympic causes thyroid C-cell tumors, which is why U.S. regulators have issued a Black box warning in June 2026 to the drug advising against its use in those with a private or family history of related conditions.

But mice usually are not people. There are human thyroid C cells. Less sensitive to GLP-1 drugs in comparison with rat C cells because they’ve fewer GLP-1 receptors. Long-term studies in monkeys didn’t show the abnormal thyroid cell growth seen in rats.

A 2025 evaluation of knowledge from 93 clinical trials was found No clear link Between taking certain GLP-1 drugs and thyroid cancer. European regulators reached out. Same result 2023 after reviewing the available research on GLP-1s.

Pancreatic cancer was one other concern. Here too, the researchers found An ever-increasing threat In a 2025 evaluation of knowledge from 62 studies taking GLP-1 drugs.

Assurance is real but temporary. These drugs are young, and Cancer can take decades to surface..

The cancer story is turned on its head.

GLP-1 drugs, once investigated for possibly causing cancer, at the moment are being debated as having the potential to stop and even treat cancer.

A 2024 study found greater than 1.6 million individuals with type 2 diabetes. Lower rates of 10 of 13 obesity-related cancers In people treated with a GLP-1 drug in comparison with insulin.

A 2025 study of nearly 87,000 adults found that overall cancer rates amongst those that began a GLP-1 drug About 17 percent lessEndometrial and ovarian cancers were also markedly reduced, in addition to a style of brain cancer called meningioma. Patients taking GLP-1 drugs had a 38% higher risk of kidney cancer, although larger studies are needed to verify this significance.

A study of greater than 110,000 women who underwent breast imaging in 2026 About 30% lower risk of breast cancer in those that use GLP-1 drugs in comparison with those that don’t.

Researchers are also studying how GLP-1 drugs affect a patient’s likelihood of surviving cancer. Among greater than 6,800 colon cancer patients in a 2024 study, 103 of 16 were on a GLP-1 drug. Died within five years in comparison with 37% of those that weren’t taking one. A study presented on the 2026 American Society of Clinical Oncology reported. The risk of death is 34% lower. in six forms of cancer for those taking GLP-1 drugs.

Why is it really easy to misread the evidence?

While these findings are interesting, studies of the results of GLP-1 drugs on cancer risk have three characteristics that make them particularly easy to misread.

The first is Healthy consumer bias. People who start a GLP-1 drug are healthier and wealthier than those that don’t. An obese one who has insurance, sees doctors recurrently and may afford Ozempic is way more prone to start the drug than someone of the identical height and weight who lacks these advantages.

The healthy consumer bias may be very difficult to beat. Observational studywhich compare people as they’re treated in real life somewhat than being randomly assigned to drugs. The very advantages that make it possible to get a GLP-1 prescription, not the drug itself, can reduce a patient’s risk of cancer.

Another comparison is drug selection. To understand the effect of a drug, it needs to be measured against something else. What it’s measured against will shape the consequence of the study. A 2024 study reported that patients taking GLP-1 drugs had a greater reduction in cancer risk than those taking insulin. But a comparison of patients taking GLP-1 drugs with patients taking the diabetes drug metformin showed. No clear reduction in cancer risk.

Insulin is reserved for patients. With more advanced diabetesA condition that itself a Cancer risk factor. In these studies, patients taking insulin started off with the next risk of cancer. Measured against a gaggle at high risk of developing cancer, almost anything can appear protective. The apparent profit got here from the comparator drug, not the GLP-1 drug.

It’s the third time. This is just not one other source of bias as a sign that other biases could also be at work. Cancer can take many years to develop, yet most GLP-1 studies follow people for less than a handful of years. In some studies, GLP-1 drug apparent cancer benefits Show up almost immediately. But prevention doesn’t work that quickly. A drug that really reduced the chance of developing cancer would show its effect regularly as tumor levels decreased over time, not in the primary few months of taking the drug.

While a patient’s risk of cancer begins to diminish almost as soon as they begin treatment, this speed is just not a magical victory for GLP-1 drugs. Rather, in my opinion, it’s telling: People who start these drugs were already at a lower risk of cancer, and the GLP-1 drugs are getting credit for the preexisting profit.

Moreover, just about all of this research comes from a handful of high-income countries, whilst using these drugs is increasing globally and the burden of cancer is increasing. disproportionately grown in low-income countries.. The concept that GLP-1s can reduce the chance of cancer in most parts of the world is being inferred almost entirely from data generated in the rich few.

What do randomized trials show?

The cleanest way around these study biases is randomized trials, which by design make the comparison groups similar from the beginning.

Available clinical trials tell a quieter story than the headlines. Two 2025 meta-analyses, which pooled data from multiple studies; One covers 50 trials. And Second Cover 48 – There is little evidence that GLP-1 drugs increase or decrease the chance of cancer.

The results of those meta-analyses are generally more reliable than those of observational studies because their total amount of knowledge increases their statistical power. Despite their strengths, these analyzes inherit the restrictions of the trials they included. Most of the trials in these 2025 studies had a brief follow-up of 1 or two years and recorded too few cancer cases to handle the query.

Randomized clinical trials designed to reply the query of whether GLP-1 drugs affect cancer risk would wish to enroll tens of hundreds of individuals and follow them for a few years. Short of that, the following best evidence will come from observational studies designed to simulate randomized trials.

Until then, the concept that GLP-1 drugs reduce cancer risk is a hypothesis that could be tested but has no results to follow.

The bottom line

Based on the available evidence, the clearest conclusion is reassuring: GLP-1 drugs don’t appear to extend overall cancer risk. However, more ambitious claims that GLP-1s actively prevent cancer or improve survival after diagnosis remain unproven.

Assume that GLP-1s impact cancer risk. Researchers still do not know where this effect comes from: Weight loss itselfa broader improvement in, or a more direct effect on, metabolic function Inflammation, immune system or tumors.

The most certain thing I can say can also be the least satisfying: it’s still too early. These drugs are far less common than the cancers they’re credited with stopping.

For many individuals living with obesity, latest weight reduction drugs comparable to Vagus And Monjaro It has caused change. These drugs are sometimes grouped under the label of GLP-1 drugs because they mimic hormones released after eating, helping people feel fuller and fewer hungry. Mounjaro, whose energetic ingredient is tirzepatide, also acts on one other hormone involved in controlling appetite and blood sugar.

At a time when greater than 1 billion people worldwide Living with obesity.These drugs are widely seen as the largest breakthroughs within the treatment of obesity. But one vital query is getting harder to avoid: What happens when people stop taking them?

The evidence points to an uncomfortable answer. Many people regain a big amount of the load they lost. A recent study It found that when people stopped weight-loss drugs, several markers of weight and heart health returned to pre-treatment levels over time. Other studies have found similar patterns after stopping. semaglutide And tirzepatide.

This makes biological sense. These drugs work partially by reducing appetite and increasing the sensation of fullness. People often describe this as a discount in “food noise,” meaning intrusive thoughts, urges, or cravings around food that could make it difficult to eat less. When treatment is stopped, those drug effects wear off. Hunger and cravings may return. If one then eats more calories than their body uses, the likelihood of regaining the load increases.

---

---

This raises the opportunity of a brand new style of weight reduction cycle.

For a long time, researchers and clinicians have warned against yo-yo weight-reduction plan, a repetitive pattern of shedding weight, gaining it back, and trying again. A pharmaceutical version of this cycle is now emerging.

One may start medication, lose considerable weight, feel healthy, then stop treatment attributable to cost, uncomfortable side effects, eligibility rules, shortages or personal preference. Over the next months, appetite returns, eating patterns change and weight reduction begins. Faced with weight gain again, they find one other prescription and begin treatment again. They shed some pounds again. Then the cycle repeats.

This shouldn’t be read as a criticism of drugs. They might be highly effective and clinically priceless for many individuals. The problem is the gap between public expectations and the fact of obesity management. Many people understandably hope that these treatments will provide a everlasting solution. But obesity is increasingly recognized as one A complex and chronic health conditionInfluenced by biology, behavior, environment and inequality. Weight management normally requires long-term help.

For healthcare professionals, GLP-1 therapy may best be viewed as a window of opportunity. Decreased appetite could make it easier to form habits that support weight maintenance, including eating commonly, being physically energetic, planning for times when cravings are almost definitely, and finding practical ways to regulate them. Medication can create conditions that make change more manageable. He shouldn’t be expected to do all of the work himself.

This calls attention to 1 a part of obesity treatment that might be fueled by excitement about latest drugs: sustained behavior change. Hunger is essential, but it surely’s only a part of an even bigger picture. Eating habits, physical activity, mental health, pain, sleep, medications, income, caregiving responsibilities, work patterns, and the foods people can easily obtain and afford all influence body weight.

---

---

Weight loss medications can facilitate behavior change by reducing appetite. They don’t robotically change the conditions during which people live. This may help explain why support focused on solving long-term habit and behavioral problems stays vital, even when medication is used. When people develop a routine that they’ll maintain, a few of these changes may proceed after this system ends, although many individuals find it difficult to maintain the load off.

The implications extend beyond individual patients. As demand for GLP-1 and related drugs increases, an increasing number of individuals may stay on them for years. For individuals with severe obesity or weight-related health complications, long-term treatment could also be clinically appropriate. At the identical time, UK regulators have warned. GLP-1 drugs should not be used for cosmetic weight loss By those that don’t meet the medical criteria.

If stopping treatment often results in weight gain, some people may feel pressured to remain on the medication indefinitely. Others may cycle through courses repeatedly, particularly if access relies on private costs, NHS eligibility, provision or changes in personal circumstances.

This creates a brand new challenge. Instead of cycling through a weight loss program, some people may find yourself cycling through a prescription. Current evidence suggests that these drugs are generally protected when prescribed and monitored appropriately, but population-based use on this scale remains to be latest. Side effects, misuse, spurious products and off-label use all require caution.

None of this diminishes the importance of GLP-1 and related drugs. They have provided advantages that previous treatments have struggled to realize. But the subsequent query for obesity drugs could also be less about how much weight people can lose while taking them, and more about what help people need in the event that they stop.

If long-term success depends entirely on suppressing appetite with medication, the familiar cycle of weight reduction and regain may not end. It could easily tackle a brand new form, tied to a prescription pad as much as a weight loss program plan.

Peptide will not be the Oxford Word of the Year for 2026 just yet, nevertheless it’s definitely within the running.

From your friendly neighborhood influencer to gym bros, injectable peptides are throughout social media and now making mainstream news when things go terribly incorrect.

People are taking them, and promoting them, for a seemingly limitless list of reasons. Depending on who you ask, they’ll either pump your feet, provide you with a tan, lighten your skin, and even construct your muscles.

But for those of us not immersed on this latest type of chemical popular culture, what are they?

---

---

They are chemical messengers.

Many peptides occur naturally within the body (endogenous), or in our food (exogenous). These are short chains of amino acids. Shorter than protein And are completely natural.

However, there are peptides created in labs for various purposes. artificial.

contained in the body, Peptides Act As health-related chemical messengers that regulate vital processes reminiscent of metabolism, growth, immunity, and Tissue repair and reconstruction.

They are water soluble, so that they cannot pass directly through cell membranes. Instead, they bind to receptors on the surface of goal cells to trigger events contained in the cell.

Some key forms of peptides include:

• Peptide hormones (eg Human growth hormone). They regulate metabolism, growth and other whole body processes.

• Neuropeptides (endorphins). These signals inside the brain and nervous system affect things like mood, appetite and pain.

• growth aspects (IGF-1). They stimulate cells to grow, divide and repair.

• Immune modulators (thymosin alpha-1). They tune or reduce the immune response.

Some commonly used drugs are peptides.

Some peptide drugs are familiar and legit: InsulinFor example, there’s a peptide hormone that has a protracted history of clinical use.

People at the moment are taking peptides for a wide range of reasons, including weight reduction – for instance Glucagon-like peptide-1 (GLP-1) receptor agonists that suppress appetite and slow gastrointestinal function.

These peptides are commonly prescribed for diabetes control or weight reduction.

Others are used for ‘correction’

gave Recent boom Peptide talk and use For most Products are advertised online for simpler weight reduction, muscle growth, injury recovery, tanning, antiaging, libido, energy, or “optimization” (the search to enhance you).

Most people using these products will not be injecting right into a vein. Peptides are frequently injected under the skin (under the skin) using small insulin-style needles. Abdomen, thigh or upper arm.

Others can be found as nasal sprays, tablets or creams. But there’s an injection The most common way to reinforce online promoting peptides.

This peptide enhancement is only one aspect of a broader push toward human “enhancement,” where the road between treating disease and enhancing a healthy body continues to blur. Social media is getting used. Normalization of enhancersIncluding peptides, beyond the elite sport.

However, because there isn’t any routine surveillance of peptide use in Australia, we don’t yet know which peptides are mostly used or how use patterns are changing over time.

How are peptides regulated?

In Australia, there are peptide products used for therapeutic purposes. Regulated as therapeutic equipment.

Many products at the moment are being advertised or sold online. Not approved They haven’t been assessed by the Therapeutic Goods Administration (TGA), ie for safety, quality or effectiveness. These include BPC-157 (promoted for injury and intestinal repair), retatrotide (an experimental weight reduction and diabetes drug), GHK-Cu (promoted for skin and antiaging), TB-500 (promoted for injury recovery) and CJC-1295 (promoted for muscle growth).

without TGA approvalIt is against the law to import or supply them for human consumption without permission.

However, people still are Access to these materialsthrough most online vendors. Social media may be very necessary to this market and driving sales. Influencers drive referrals and inject products online and tell people how they may make their skin glow.

A serious drawback is that suppliers use these substances to sell them. In America Labeling them “research chemicals” or “research use only”. But that does not imply these substances are legal or secure for human consumption. Nor does it apply in Australia.

---

---

What are the risks?

The biggest threat is not at all times the peptide itself. Products to extend online sales May contain Too much – or too little – of the advertised ingredient in comparison with what the label claims.

Our Recent laboratory testing The dose of retatrutide was found to be roughly double the labeled amount.

Other products May contain Impurities, contaminants or completely different substances

Even a properly labeled, uncontaminated product poses a risk. Most growth peptides have little or no human trial data, so their effects and safety in healthy individuals are largely unknown.

Self-injection introduces the risks of infection, abscesses and wounds, in addition to blood-borne viruses if equipment is shared.

Many individuals who use enhancement drugs reminiscent of peptides don’t disclose their use to health and drug services, meaning they I remember On harm reduction advice, sterile injection equipment and accurate health information.

What must be done?

As peptide use increases, Australia must:

• Integrated surveillance to observe emerging products and losses

• Proceedings on internet marketing and sale of those products: Implementation of existing laws Against Advertising Unapproved Therapeutic Goods and holding platforms accountable for referral link sales

• Better education for clinicians increasingly encountering peptide use of their clinical practice.

• Evidence-based information that reaches people through the identical online platforms where these products are promoted.

• Research on the broader “augmented” ecosystem, including how people move between products, where they get information and use protocols, what escalates, and the way online communities influence norms around risk.

Harm reduction, health education and online literacy shall be critical if we’re to stop avoidable injuries while evidence continues to develop.

Weight loss jabs are the newest craze to shed a couple of kilos. With drugs resembling Ozempic and Wegovy (semaglutide), their effect has been dramatic, causing users to Up to 15% damage Average their body fat.

Semaglutide, which is a glucagon-like peptide 1 (GLP-1 receptor agonist medication) mimics Natural gut hormone action Which is released after we eat.

This gut hormone stimulates a lot of physiological responses that play a job in regulating body weight, resembling releasing insulin to assist control blood sugar levels, slowing stomach emptying (so we feel fuller longer) and even telling the brain’s hunger centers to suppress hunger.

But as effective as GLP-1 drugs are, not everyone who uses them will lose enough weight. The so-called “non-respondents” are those that Less than 5% loss After about their body weight Six months Treatment at essentially the most tolerated dose. Research suggests that Between 10% and 30% Patients fit into this group.

Many people who find themselves labeled as non-responders to GLP-1 receptor agonists resembling semaglutide don’t take the medication appropriately or stop treatment before achieving an adequate therapeutic effect. Studies show. Up to 20-60% of people People stop treatment throughout the first 12 months, and the drug is widely utilized in doses lower than really useful.

sure Metabolic problems As with insulin resistance, where the body’s cells stop responding properly to insulin, semaglutide may stop working. Sleep disturbance It may block the drug’s effects, as lack of sleep delays the discharge of the body’s natural GLP-1 hormone.

People taking other medicines, eg Corticosteroids And Psychiatric drugs (resembling antidepressants) that could cause weight gain can also find that GLP-1 drugs don’t work as well for them.

But these usually are not the one the explanation why an individual could also be labeled non-responsive.

Interestingly, sex may play a job in how an individual responds to those drugs, with studies showing that ladies taking semaglutide consistently lost more weight than men.

A review of 47 randomized controlled trials involving greater than 23,000 patients found that The biggest effect is weight loss GLP-1 drugs were shown in participants who were young, female and never diagnosed with diabetes (in order that they were higher off). Insulin sensitivity).

One reason women respond higher could also be due to them. High estrogen levels. This hormone improves insulin sensitivity and stimulates the discharge of GLP-1.

Another reason some people respond poorly to GLP-1 drugs is their genetic makeup.

Scientists have identified variants within the gene coding for the enzyme. PAM (peptidyl-glycine alpha-amidating monooxygenase) which causes GLP-1 resistance. This genetic mutation is carried by about 10% of the population.

Individuals with this genetic mutation have high circulating levels of GLP-1 but without the expected biological effect. This implies that more GLP-1 hormone is required to realize the identical response in people without the mutation. This indicates clear resistance to the hormone.

Research that checked out the genetics of nearly 28,000 people taking GLP-1 drugs also identified this. Genetic problems Another set of receptor genes called GLP-1R and GEPR.

This genetic issue led to differences in each weight reduction and unintended effects. People who had these genetic problems had the next body mass index (BMI) and body mass on average, and were more more likely to develop type 1 diabetes and other metabolic problems. Such genetic differences may explain why some people fail to drop some pounds when taking a GLP-1 drug.

Another factor that will contribute to non-responders is expounded to the causes of obesity itself. Our body works on its basis. Four different types of hunger. If a drug targets something that isn’t the underlying reason for an individual’s obesity, the response seen will likely be small.

The first type is our basic slow-burn appetite, which is the minimum variety of calories our body absolutely must eat to operate (also often known as our metabolic rate). Another variety of hunger is the hungry gut, which has to do with the actual, physical need for food. gave The way we eat It will also be driven by our brain (often known as the hungry mind, where we eat out of habit or stress) or our emotions (often known as emotional hunger, where we eat to address how we feel).

For patients with anorexia nervosa, GLP-1 medications don’t address the underlying reason for the person’s overeating anxiety and depression. According to an observational study Conducted in Japan, impulsive eaters were less more likely to see significant weight change when using GLP-1 drug treatment.

Integrating cognitive behavioral therapy can due to this fact be vital for many who struggle. Emotional hunger and are used as GLP-1 drugs. for A hungry gut Patients, a high protein, high fiber weight loss program can increase the effectiveness of the drug.

for Patients with hungry brainsswitching to dual agonists resembling tarzapatide (known commercially as Monjaro), which targets two digestive hormones, GLP-1 and glucose-dependent insulinotropic peptide (GIP), could also be useful. for Slow burn Appetite, resistance training can increase resting metabolic rate.

Although weight reduction drugs have proven effective for many individuals, the indisputable fact that they don’t work for everybody shows how vital it’s to maneuver toward developing the suitable obesity medicine. This involves analyzing a patient’s unique genes and lifestyle patterns to match them. The right medicine. Although genetic testing for variants related to non-response isn’t common, it represents the following step in helping to make sure that patients are given the treatments that work best for them.

When it involves weight reduction, the fear of “ruining your metabolism” is widespread. In fact, many individuals who’ve lost weight after which put it back on find that every failed attempt leaves them worse off than before, with more fat, less muscle, more hunger, less energy, and an ever-diminishing ability to shed pounds again.

For those that need to shed pounds, the so-called “yo-yo effect” has develop into an almost constant threat. According to this theory, losing and regaining weight is just not only frustrating but additionally dangerous. It even leads some people to consider it. They are better than not trying. Absolutely to shed pounds.

nonetheless, A critical review published in The Lancet Diabetes and Endocrinology This idea calls for a re-examination. The authors review the available evidence on “weight cycling”—repeated cycles of weight reduction and regain—and conclude that there isn’t any solid evidence that the phenomenon itself causes it. Long-term medical harm in people with obesity.

Nuance is essential here. This doesn’t mean that weight regain is obligatory, nor that each eating regimen is an excellent idea. This highlights something else: current evidence doesn’t support the claim that losing a few pounds after which regaining it “breaks” the metabolism or necessarily leaves an individual worse off than before.

This finding is essential because fear of the UU effect generally is a barrier to looking for help, making changes, or resuming healthy habits after weight gain. And provided that obesity is a chronic and recurring condition, suggesting that every failed try to cause irreversible damage can result in feelings of guilt, despair, and resignation.

---

---

What we all know – and do not know – about weight cycling

Part of the confusion arises in several ways. Observational studies have been interpreted.. People who’ve undergone multiple cycles of weight reduction and regain have more difficulty maintaining their weight reduction, in addition to higher body fat and obesity for longer years. More metabolic abnormalities are observed in these groups, nevertheless it is just not at all times easy to separate causes from effects.

To put it one other way, the incontrovertible fact that an individual with poor metabolic health has been on a eating regimen doesn’t prove that the eating regimen caused the deterioration. The opposite could also be true: excess body fat, an extended history of being obese, or the prior presence of risk aspects can all be the cause. High number of weight loss attempts and poor health outcomes.

Unwarranted fear of muscle loss

One of probably the most common fears when starting a eating regimen is the lack of muscle mass. When losing a few pounds, the body doesn’t just lose fat; It may also lose some lean body mass. The fear related to the yo-yo effect stems from the incontrovertible fact that when weight is regained, fat is regained as an alternative of muscle, resulting in An increasingly unfavorable body composition.

However, in accordance with a recent Lancet review, available data don’t consistently reveal a disproportionate and sustained lack of lean body mass attributable to weight cycling itself. Results rely upon many aspects, including the ultimate weight achieved, the quantity of protein in an individual’s eating regimen, the sort of intervention, the extent of physical activity and particularly the presence (or absence) of strength training.

The same thing happens with energy costs.. The common belief is that each one food slows down the metabolism, but metabolic rate is greatly affected by body size and composition. If an individual is underweight, he also needs less energy to run his body, and if he gains weight, the energy expenditure adjusts accordingly. This adaptation doesn’t necessarily equate to a everlasting metabolic disorder.

---

---

Lose weight

Here’s a crucial caveat: Dispelling the “broken metabolism” myth That doesn’t mean we can take weight regain for granted.. When an individual loses weight, their blood pressure, blood sugar levels, lipid profile, mobility, sleep and quality of life can all improve. If they regain the lost weight, a few of these gains may diminish or disappear, returning the person to their original metabolic state. But that does not prove that losing a few pounds after which regaining it causes any additional damage.

This is one in all the principal points of the article. The principal problem is just not attempting to shed pounds, but difficulty maintaining an appropriate and healthy weight reduction over time.

This importance can be vital within the era of recent obesity drugs, including GLP-1 receptor agonists resembling Ozempic and other similar treatments. In many cases these drugs cause significant weight reduction, but discontinuation may end in partial or complete weight reduction. But it’s too simplistic to interpret this rebound as evidence that treatment disrupts metabolism — making it more likely that obesity requires long-term treatment strategies. Just like other similar situations.

There is not any miracle eating regimen.

The conclusion mustn’t be that yo-yo weight-reduction plan is not any big deal. This is usually accompanied by frustration, guilt, low self-esteem, lack of healthy habits, and a deteriorating relationship with food. It may also depend on poorly thought-out practices, resembling overly restrictive diets, unrealistic goals, lack of adequate support, or an exclusive, reflective concentrate on the number on the scales.

We should never suggest that regaining weight means one has irrevocably failed. Many individuals who manage to take care of significant long-term weight reduction accomplish that only after several failed attempts. When it comes to creating healthy decisions, change isn’t linear.

---

---

The best theoretical and practical approach is to interchange the mindset of temporary abstinence with a sustainable lifestyle. This means setting realistic goals, maintaining muscle mass, avoiding extreme restrictions, selecting filling and nutritious foods, recovering sleep, being more energetic, and looking for skilled help where possible. in brief, Long-term restraint is more important than any other variable..

It also means understanding that body weight is controlled by powerful biological systems. After losing a few pounds, the body can increase feelings of hunger, partially reduce energy expenditure, and promote recovery. This is just not an indication of private weakness, but an adaptive response. This is why maintaining weight reduction normally requires a long-term approach. Not just willpower.

A well-designed intervention should include adequate protein, strength training, regular physical activity, dietary satisfaction, nutrition education, ongoing monitoring, and psychological or behavioral support where obligatory. In some cases, it might also require drug therapy or bariatric surgery. The selection relies on the degree of obesity, comorbidities (presence of several conditions at the identical time), medical history and individual preferences of every individual.

Fighting with despair

Regaining weight does not imply your metabolism is broken. Nor does it mean it isn’t value trying again. It simply means your previous perspective wasn’t enough, was unsustainable, or you lacked the right support..

The recent review doesn’t condone fad diets, nor does it present the yo-yo effect as harmless. What it does is debunk the more specific and counterintuitive notion that losing a few pounds and regaining it can necessarily damage the metabolism.

When it involves obesity, as in lots of other areas, a failed attempt mustn’t be seen as the top of the road, but as a guide to planning the following step.

---

---

A high body mass index (BMI) is certainly one of the main risk aspects for developing osteoarthritis. But a brand new study suggests that carrying extra weight also makes it more likely that an individual will develop an inflammatory joint condition, akin to rheumatoid arthritis.

The study was published online by the journal May 23, 2023. Arthritis and RheumatologyAround 362,000 adults participated within the UK Biobank, a big biomedical database. Researchers analyzed how participants’ BMI — a calculation of body size that takes into consideration height and weight — related to their likelihood of developing any of 5 joint conditions: rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout, and inflammatory spondylitis (a variety of spinal arthritis). Except for osteoarthritis, most joint diseases are brought on by inflammation.

Participants with a high BMI (those significantly above the “normal” BMI range of 18.5 to 24.9) had higher BMI rates for rheumatoid arthritis (52%), osteoarthritis (49%), psoriatic arthritis (80%), gout (73%) and inflammation (43%) than in the overall population. The study authors concluded that weight control may help reduce the chance of developing joint disease.

Photo: © EasyImages/Getty Images

Losing weight is difficult. Keeping it away is usually even harder.

Research has shown that the majority individuals who drop a few pounds intentionally. At least get some of it back. in a couple of years. This is Often attributed to a lack of “power”.but evidence actually shows that after shedding pounds, the body undergoes many biological changes that encourage weight regain. This includes increased appetite, changes in metabolism and changes in hormones involved in appetite regulation.

Even individuals who Less weight Using GLP-1 medication makes it difficult to take care of their weight reduction. Once treatment is stopped.

For this reason, finding ways to assist people maintain weight reduction is a vital area of ​​research.

A brand new study published in Nature Medicine suggests. A special gut microbe May help prevent weight regain.

The bacterium, because it known as, is one. Abundant species In the human gut microbiome. It lives within the mucus layer that lines the intestine. It is capable of feed on mucin (the proteins and sugars that make up this mucus), and is believed to play a job on this. Maintaining the intestinal protective barrier Can do more Affects metabolism..

has attracted attention in microbiome research lately attributable to its association with Better health outcomes in multiple diseases.

Studies in humans have shown that higher levels are related to higher metabolic health, including Better blood sugar controlwhich reduces the chance of developing health problems akin to type 2 diabetes. alternatively, The lower level of Seen in individuals with obesity and sort 2 diabetes.

This recent study investigated whether giving people extra food after weight reduction could help them regain the burden later.

The trial involved 90 adults who were chubby or obese. Participants followed a low-energy food plan for eight weeks. This includes meal alternative soups and shakes totaling 800-900 calories per day.

After this phase, participants who had lost at the very least 8 percent of their body weight were then randomly assigned to receive a placebo or each day supplements for twenty-four weeks. They were also instructed to follow a healthy food plan that suited her. Dutch Dietary Guidelinesbut they were told they may eat as much as they wanted.

Live bacteria weren’t utilized in this study. Instead, they used a pasteurized version (meaning the bacteria had been treated with heat and were not alive). This may sound counterintuitive, but Previous research suggests that a number of the helpful effects of probiotics, including, may come from bacterial cell components slightly than live microbes. Pasteurization can also increase Effects of microbes.

By the tip of the study, the gainer group had gained significantly less weight than the placebo group. On average, those taking the complement gained about 1.2 kg, in comparison with 3.2 kg within the placebo group. This suggests that after the initial weight reduction, supplementation slowed, but was not completely stopped.

The researchers also saw some improvements in some cardiometabolic markers, including improved insulin sensitivity (meaning the body is responding more effectively to insulin) within the complement group.

Gut microbiome and body weight

The microbiome is amazingly complex. is affected by Diet, exercise, sleep, medication And many other aspects. As a result, microbiome-based therapies are unlikely to be easy, one-size-fits-all solutions.

Although the outcomes are encouraging, the study was relatively small and lasted only six months after the initial weight reduction phase. We don’t yet know if the results will last long.

There are also questions on who’s most probably to learn, as participants with lower baseline gut levels show greater cardiometabolic improvement. This highlights a broader challenge in microbiome science: People’s gut microbiomes vary greatly, and coverings that work well for one person can have little effect in one other.

The study also included substantial dietary intervention and support, including provision of a meal alternative plan for initial weight reduction, and support from a dietician throughout the study period. Therefore, microbes haven’t been tested in isolation from lifestyle changes, nor should they be viewed as an alternative to them.

It can be value noting that several authors declared affiliation with the corporate that manufactured the complement utilized in the trial. While such collaborations are common in translational research (studies that test laboratory leads to real people to know health advantages), independent studies might be necessary to substantiate and construct on these findings.

That said, the microbiome remains to be an exciting and increasingly necessary area of ​​research with clear relevance to many features of human health. Our understanding of this remains to be evolving. nevertheless, Research so far suggests that that the microbiome plays a key role in metabolism and immunity, meaning it might influence each health and the event of disease.

Many probiotic supplements are currently marketed to consumers. Limited evidence behind them. Although studies akin to these suggest that rigorously targeted microbiome therapies may eventually have the potential for use as a part of weight maintenance strategies, rather more research is required.

It is even possible to contribute and add with none complement. It plays a vital role in food plan. Composition of the microbiome. Fiber-rich foods, especially prebiotic fiber (a form of dietary fiber that feeds helpful gut bacteria), can assist create an environment through which helpful bacteria, including can develop.

---

---

These fibers are present in foods like onions, garlic, leeks, asparagus and plenty of whole grains. Plant foods high in polyphenols (naturally occurring plant compounds that may protect against cell damage and inflammation) – akin to berries and grapes – It can also promote its development..

For now, the outcomes of this study add to the growing body of evidence that body weight is influenced by a posh interaction of biological, environmental and behavioral aspects. They also contribute to an increasingly clear picture of the gut microbiome. Key regulator of metabolism and health.

Even before receiving public funding, Vagus It has attracted media attention in New Zealand for the dramatic difference it might probably make to weight reduction.

But as their popularity has grown, so has the controversy about what it means for these next-generation drugs to essentially go bad. The obesity crisis And his reasons for driving.

Last month, New Zealand’s drug funding agency Pharmac Wegovy added For that List of medicines suitable for public funding in the longer term. If it does – and this Can do it quickly – The drug will initially be targeted at individuals with severe obesity, or those that are obese with associated health conditions.

Now, of medicine Private prescription costs – upwards of NZD$400 per 30 days – puts it out of reach for a lot of New Zealanders, particularly those disproportionately affected by obesity. This has strengthened arguments that public funding can improve equity while reducing long-term health care costs.

All the time, New Zealand Reporting continues Some of the best obesity rates within the developed world. Today, one in three adults and one in eight children are obese, while nearly two-thirds of adults are either obese or obese.

This could make public funding prospects for the country and its health system more attractive. But it must even be asked: Can these drugs really be expected to tip the scales against an epidemic rooted in complex social and environmental aspects?

Why are we hearing about Vegovi?

Vagus Works through semaglutide.a drug that helps control appetite and blood sugar, making people feel fuller for longer.

Clinical trials show that, when the drug is combined with lifestyle changes, the consequences will be surprising. i A Historical StudyParticipants lost about 15 percent of their body weight over 68 weeks, significantly greater than those taking a placebo.

For some people, such weight reduction will be life-changing – reducing the danger of diabetes, heart problems and other long-term conditions.

Still, the drug has drawbacks. People normally have to keep taking it to take care of weight reduction, and plenty of people regain weight after treatment stops. Side effects are common, and long run Be uncertain.

New Zealand Food ‘Swamps and Refuges’

The debate about latest drugs reminiscent of Vigovi can sometimes reduce obesity to an issue of non-public alternative and responsibility.

But obesity in New Zealand has been on the rise for many years, particularly amongst children and more deprived communities, reflecting drivers that transcend individual behaviour.

Research shows that the environment people live in, for instance, strongly reflects what and the way they eat. Highly processed, energy-dense foods are widely available today, aggressively marketed and infrequently cheaper than healthier options.

But some sections of society are more exposed than others. Māori and Pacific communities experience significantly higher rates of obesity, reflecting wider inequalities in income, housing and access to healthy food.

Fast food outlets are disproportionately concentrated in additional deprived areas and are “A swamp of foodUnhealthy options are common in New Zealand. In many neighborhoods, unhealthy food is common The easiest and most accessible alternative.

Children’s on a regular basis environments also play a job. Studies suggest. Many New Zealand schools still facilitate access to unhealthy food, with healthy food policies unevenly implemented.

Yet there are signs that it really works. so-called “Food sheltersCommunity spaces designed to make healthy eating inexpensive, accessible and culturally appropriate – show how local initiatives can improve food environments.

Interruption, but no response.

All of this reinforces that obesity is basically one. System problemnot something that will be solved by pharmaceutical treatment alone. Framing these drugs as a silver bullet risks distracting attention from the broader safety changes needed to handle the foundation causes.

There are also policy tensions. Public funding for Vigovi could actually help reduce future health care costs by reducing rates of diabetes and heart disease. But unless the drivers of obesity are addressed, the number of individuals needing treatment will proceed to rise.

Evidence suggests that interventions are needed to scale back obesity on the population level. Environment which shapes on a regular basis life.

This includes improving access to inexpensive healthy food, curbing the marketing of unhealthy products, strengthening school food environments and addressing broader social and economic conditions that influence health.

These interventions are clearly more complex than prescribing medication. But also they are more more likely to find a long-lasting solution to the crisis that’s taking a heavy toll on New Zealand yearly.

For many years, people have been told that their weight problems may be solved with math: calories in, calories out. If weight were a straightforward mathematical equation, most individuals would likely be the burden they need to be. But it’s way more complicated.

are Many theories Why shedding pounds is difficult. Some give attention to genetics and metabolism while others claim that environmental and social aspects are more essential. But which of those theories is correct, if any? Is people’s weight determined by their genetics, metabolism or environment?

I’m a diabetes specialist and Doctor specializing in obesity medicine. Understanding what is understood and what’s uncertain about these theories can allow you to take control of your biology to potentially change your weight.

Set the burden of the purpose.

The concept of Set point weight Has been for the reason that Nineteen Fifties. This suggests that the body has a regulatory system that defends a predetermined level of adipose tissue – commonly called fat – that it maintains by altering hunger signals and energy expenditure. This predetermined fat level is governed by genetics, physiology and environmental aspects.

This idea is supported by observations that after weight reduction, Appetite increases and energy expenditure decreases. until the burden is restored. In theory, this process prevents the body from ravenous itself, even with significant weight reduction. One study found that hormones that cause hunger are elevated and hormones that cause fullness are suppressed. At least 62 weeks after weight lossand even after regaining weight.

is known as a relational concept Metabolic adaptation It seems to affect energy balance, although evidence for this effect in people is less clear. This process implies a greater reduction in energy expenditure than can be predicted from changes in body composition. In other words, as you drop some weight, you burn fewer calories than can be expected for somebody of the identical weight who has not lost recent weight.

Metabolic adaptations manifest as increased and decreased appetite. Resting metabolic rateis the energy you burn to take care of background processes comparable to heart rate, temperature regulation, respiration and digestion, even when you lie in bed all day. In metabolic adaptation, Metabolic rate decreases at rest. After about 5 percent weight reduction. Energy burned from exercise decreases by about 10 percent after weight reduction.

This implies that as an individual loses weight, the quantity of energy used for background processes to survive decreases. Additionally, an individual should increase exercise as they drop some weight to see sustained weight reduction. So the more weight an individual loses, the tougher it’s to lose more weight.

This reduction in energy expenditure can persist for years after weight reduction, as seen in a single study. Participants in the TV show “The Biggest Loser”.However, some studies have found metabolic adaptations. Don’t be so important. As once thought.

There are several strategies to manage set-point weight and the metabolic adaptations expected with weight reduction. Bariatric surgery – A mechanism for weight reduction – Set point seems to change weight, reduce appetite without reducing energy expenditure and patients are rarely underweight. GLP-1 and similar drugs May not affect metabolic adaptations during weight reduction. Nutrition strategy These include increasing protein intake, reducing glycemic load and high-fiber diets, although evidence for the effectiveness of those strategies varies.

Set point indicates that your body has a set weight it likes to remain at and can adjust your metabolism and appetite to get you to it and keep you there.

Settling point model

An alternative theory for assigning point weights is known as Settling point. This model suggests that weight regulation occurs through passive feedback without biological control. Rather than the body actively controlling weight through changes in hormones, this theory suggests that body weight is a results of your habits and environment.

The settling point is defined as where body weight stabilizes as energy intake equals energy expenditure. It is set by Physiological and metabolic costs of maintaining body mass. People with the next body mass expend more energy resulting from the increased energy required to maneuver and maintain a bigger body. Therefore, people living in a bigger body need more food.

Settling point may sound just like the old “calories in, calories out” model, nevertheless it also Considers environmental and social impacts.. Think of it as an open window. A room may be warmed by sunlight throughout the day, then cooled overnight. Over time, the room will hover around the identical temperature. The temperature just isn’t fixed but will naturally settle based on weather, insulation and airflow. It may be cold in winter and hot in summer.

Now let’s apply this idea to an individual. If you might have a job where you’re in your feet all day and eat home-cooked meals more often than not, your weight could also be stable. If you turn to a desk job and begin eating high-calorie foods and enormous portions, your weight may increase until it stabilizes again. In either case, your weight eventually stabilizes at different settling points based in your current circumstances.

However, the settling points theory fails to clarify the biological and genetic points of weight.

Dual intercept point model

gave Dual intercept point model The set point integrates each the burden and the settling point. This theory proposes an upper and lower limit that defines the bounds of everyone’s “acceptable” body weight, often known as the zone of indifference. The lower threshold is the purpose at which hunger is stopped while maintaining all biological and metabolic needs.

In the region of indifference, concepts of the settling point prevail: the body will adjust to the energy and environment. But when body weight drops below a threshold, it prompts physiological mechanisms to forestall further weight reduction and forestall starvation. gave Hormonal systems of the body Increasing appetite and reducing energy expenditure.

When body weight exceeds an upper limit, biological mechanisms should theoretically engage to forestall further weight gain. Researchers have documented this process. Many studies in animalshypothesizing that that is most certainly resulting from the increased risk of predation from weight gain. Animals with an excessive amount of fat are targeted or cannot escape from predators. However, this process Not always seen in people And there may be weak evidence to support this.

The dual intercept point model also suggests that The zone of indifference varies widely. between individuals. This would explain why some people maintain a comparatively stable weight and others have more fluctuations over time. Some may recognize this because the old struggle of “losing the same 10 pounds over and over again.”

Additionally, Drifting gene hypothesis suggests that the upper limit for body interference has progressively moved upward as people have moved to safer, more stable environments. Evolutionary pressures to take care of a lean body for survival, comparable to avoiding predators like a hungry tiger, have largely disappeared.

Which theory carries essentially the most weight?

So which theory of body weight regulation is correct? The answer is that none of them quite fit real-world experiences. But plainly how your metabolism responds to lively weight reduction is different than weight maintenance, so the approach to every goal could also be different.

Reducing food intake appears to be most useful. Achieving weight loss. On the contrary, exercise seems to The key to weight maintenance.

Overall, the large advantage is that the burden balance is complicated. This just isn’t a simple arithmetic problem to resolve. Appropriate medical take care of obese and obesity includes nutrition, exercise, sleep, stress, and other aspects affecting weight. Changes in these aspects may be combined with medication or surgery to attain everlasting weight reduction.

Weight loss is usually not linear, and plateaus are expected. Each case is individual, and one size – or theory – doesn’t fit all.

Regulating blood levels of cholesterol is one method to prevent heart disease and stop heart attacks and strokes. Doctors give attention to helping men lower blood levels of low-density lipoprotein (LDL), or “bad” cholesterol. Too much LDL within the bloodstream could cause plaque to accumulate contained in the arteries. If this build-up blocks blood flow to the guts or brain, the result’s a heart attack or stroke.

Your goal level for LDL is dependent upon your risk factor profile. In general, the lower the number, the higher. If you have already got heart disease or are at high risk for it, you must aim for an LDL of lower than 70 milligrams per deciliter (mg/dL). For people at average risk, achieving levels below 100 mg/dL with lifestyle changes is best. You and your doctor can resolve in case you need a statin or other medication to further lower your LDL.

But what about LDL’s cholesterol counterpart, high-density lipoprotein (HDL), the “good” cholesterol?

When is nice HDL good?

HDL is taken into account “good” because it really works well. It patrols the blood vessels, collects excess cholesterol from the bloodstream and artery partitions, and transports it to the liver, where it’s faraway from the body. This ongoing motion prevents dangerous plaque build-up. Guidelines recommend an HDL level of 40 mg/dL to 60 mg/dL for adult men. “A level below 40 mg/dL may mean that there is not enough HDL to function properly,” says Dr. Sachs.

Since HDL is taken into account “good,” it could make sense that higher amounts equate to additional protection. But research has shown that this shouldn’t be necessarily true, and that HDL levels above 80 mg/dL don’t offer additional advantages.

High HDL may not at all times be effective since it needs help to do its job. Research shows that HDL’s protective role depends partially on levels of LDL and triglycerides (a style of blood fat that helps make up your lipid profile). A study that checked out individuals with high and low levels of HDL and other people with normal and high levels of LDL and triglycerides found that healthy levels of all three are needed for optimal protection against heart disease.

Do you would like advanced lipid testing? Doctors use lipid panels to measure levels of cholesterol, screen people for heart disease risk, and monitor treatment. Still, sometimes more detailed cholesterol information is required. This requires advanced lipid testing to measure the essential protein apolipoprotein B (apoB) in LDL. Research has suggested that higher levels of APOB may indicate higher risk.

On the rise

A normal blood test called a lipid panel measures an individual’s total cholesterol, LDL, HDL, and triglycerides. Certain people may profit from advanced lipid testing (see “Do you need advanced lipid testing?”). The results help predict the chance of heart disease and indicate whether treatment is required.

Addressing high LDL is at all times the primary priority, but when you might have low HDL levels — lower than 40 mg/dL — your doctor will likely recommend lifestyle changes, based on Dr. Sachs. “While a person’s HDL level is determined primarily by genetics, certain habits can cause HDL levels to drop,” he says. Here are some strategies that individuals with low HDL should adopt.

Exercise more. Moderate exercise, akin to brisk walking for no less than half-hour thrice every week, might help raise HDL. High-intensity interval training may help.

Lose weight. If obese, aim to lose 5% to 10% of your current weight.

Reduce refined carbohydrates. Switch from refined carbohydrates (white bread, white pasta) to whole grains (oats, whole-wheat pasta, brown rice) and add lean protein to your food regimen, akin to chicken, tofu, beans and lentils.

Limit alcohol. Keep your intake, if any, to at least one to 2 drinks per day.

Stop smoking. If needed, get medical help to quit.

Photo: © Dilok Klaisataporn/Getty Images